Is your company considering an Rx-to-OTC switch for one of your brands? FDA's approval of two first-in-class Rx-to-OTC switches in 2013 coupled with their announcement of the Non-prescription Safe Usage Regulatory Initiative (NSURE) has increased interest in evaluating future switch candidates as part of life cycle management. It’s important to do a thorough evaluation before starting a switch development program, including understanding the regulatory criteria, the current market potential, and learning from the performance of past switches. Join this introductory webinar to understand the current influences that are affecting the opportunity for Rx-to-OTC switches for the OTC industry.
January 15, 2014
You must be logged in to access CHPA Subscriptions.
To continue, you need to log in to CHPA. If you have any questions about your account please contact us at 1-866-702-3278.
CHPA Member Price:$199.00